Allo-HSCT still has a role in the management of patients with CML. Despite excellent results with TKIs, HSCT remains an important treatment option in a subset of patients. We believe HSCT will offer these specific patients a chance for a long-term control of their disease and even a cure. This subset of patients comprises: patients in chronic phase of disease failing at least two TKIs or those intolerant to all TKIs available, including patients with T351I mutation not responding to ponatinib; all patients in blast crisis; patients in accelerated phase of disease who do not achieve a continuous, stable and deep response to TKI; and very young patients – in childhood and adolescence.
We are aware of the dynamic and changing field of CML treatments. There is a vast research and new compounds are being investigated. The major targets of this research are overcoming resistance to TKI and finding cure for CML. Never-the-less, HSCT is and will be in the near future the best, and sometimes the only, option treating a subset of patients with CML.
Expert Rev Hematol. 2013;6(6):759-765. © 2013 Expert Reviews Ltd.